HSCRMAG32KPX14
MILLIPLEX® Human Soluble Cytokine Receptor Panel
Premixed Human Soluble Cytokine Receptor 14-Plex Panel
别名:
Human Cytokine Receptor Multiplex Kit, Luminex® Human Cytokine Receptor Immunoassay, Millipore Cytokine Receptor Panel
登录 查看组织和合同定价。
选择尺寸
变更视图
关于此项目
UNSPSC Code:
12161503
NACRES:
NA.47
eCl@ss:
32161000
产品名称
MILLIPLEX® Human Soluble Cytokine Receptor Panel,
description
Premixed Human Soluble Cytokine Receptor 14-Plex Panel
Quality Level
species reactivity
human
packaging
pkg of 1 ea
manufacturer/tradename
Milliplex®
technique(s)
multiplexing: suitable
input
plasma
serum
cell culture supernatant(s)
assay range
accuracy: 91-104%, sensitivity: 4-208 pg/mL
(Overnight Incubation minDC), standard curve range: 12.2-50,000 pg/mL
(sIL-4R, sIL-6R, sRAGE, sTNFRI, sTNFRII), standard curve range: 122.1-500,000 pg/mL
(sEGFR, sIL-1RII, sVEGF-R1, sVEGF-R2, sVEGF-R3), standard curve range: 24.4-100,000 pg/mL
(sCD30, sgp130, sIL-1RI, sIL-2Rα), inter-assay cv: <15%
intra-assay cv: <10%
detection method
fluorometric (Luminex® xMAP® technology)
shipped in
wet ice
storage temp.
2-8°C
General description
Cytokine receptors constitute an integral part of cytokine biology. Like cytokines, cytokine receptors are involved in normal physiological and pathological processes of almost all disease states. Soluble cytokine receptors naturally arise from genes encoding membrane- bound receptors or are direct derivatives of the receptors themselves. The discovery that soluble cytokine receptors are involved in regulating excessive inflammatory responses and modulating immune events has stimulated significant research interest in their potential role as immunotherapeutic agents. Many of these soluble cytokine receptors can inhibit the binding and biological activity of their cytokine ligands, making them very specific cytokine antagonists.
Application
MILLIPLEX® Qualified assays undergo rigorous assay development, verification, and Quality Control testing to achieve optimal performance. Simultaneously analyze 14 analytes in human serum, plasma, and cell culture supernatants.
Analytes included: sCD30, sEGFR, sGP130, sIL-1RI, sIL-1RII, sIL-2Rα, sIL-4R, sIL-6R, sRAGE, sTNFRI, sTNFRII, sVEGFR1, sVEGFR2, sVEGFR3
Assay Characteristics: Refer to kit protocol for assay cross-reactivity, sensitivity, precision, and accuracy.
Analytes included: sCD30, sEGFR, sGP130, sIL-1RI, sIL-1RII, sIL-2Rα, sIL-4R, sIL-6R, sRAGE, sTNFRI, sTNFRII, sVEGFR1, sVEGFR2, sVEGFR3
Assay Characteristics: Refer to kit protocol for assay cross-reactivity, sensitivity, precision, and accuracy.
Features and Benefits
- Comprehensive Biomarker Coverage: Includes key cytokines, chemokines, and immune modulators relevant to inflammation and immune response pathways.
- Supports Mechanistic Insights: Facilitates understanding of disease mechanisms such as autoimmune disorders, infections, and chronic inflammation.
- Lot-to-Lot Consistency: Ensures reproducible results across experiments, improving data reliability.
- Optimized Panel Design: Pre-selected analytes based on verified inflammatory and immunological targets.
Legal Information
Luminex is a registered trademark of Luminex Corporation
MILLIPLEX is a registered trademark of Merck KGaA, Darmstadt, Germany
xMAP is a registered trademark of Luminex Corp
Disclaimer
For research use only. Not for use in diagnostic procedures.
Label License/Sticker for Assay Product:
By opening the packaging containing this Assay Product (which contains fluorescently labeled microsphere beads authorized by Luminex Corporation) or using this Assay Product in any manner, you are consenting and agreeing to be bound by the End User Terms and Conditions and the End User License Agreement available at http://support.diasorin.com/end-user-terms-and-conditions/. If you do not agree to all of the terms and conditions, you must promptly return this Assay Product for a full refund prior to using it in any manner.
Label License/Sticker for Assay Product:
By opening the packaging containing this Assay Product (which contains fluorescently labeled microsphere beads authorized by Luminex Corporation) or using this Assay Product in any manner, you are consenting and agreeing to be bound by the End User Terms and Conditions and the End User License Agreement available at http://support.diasorin.com/end-user-terms-and-conditions/. If you do not agree to all of the terms and conditions, you must promptly return this Assay Product for a full refund prior to using it in any manner.
signalword
Danger
Hazard Classifications
Acute Tox. 4 Dermal - Acute Tox. 4 Inhalation - Acute Tox. 4 Oral - Aquatic Chronic 2 - Eye Dam. 1 - Skin Sens. 1 - STOT RE 2
target_organs
Respiratory Tract
存储类别
10 - Combustible liquids
wgk
WGK 3
法规信息
新产品
此项目有
Laura L Jelliffe-Pawlowski et al.
Journal of perinatology : official journal of the California Perinatal Association, 38(8), 963-972 (2018-05-26)
To evaluate if mid-pregnancy immune and growth-related molecular factors predict preterm birth (PTB) with and without (±) preeclampsia. Included were 400 women with singleton deliveries in California in 2009-2010 (200 PTB and 200 term) divided into training and testing samples
Lingkun Kong et al.
Investigative ophthalmology & visual science, 57(4), 1649-1654 (2016-04-08)
We compared changes of plasma angiogenesis cytokine profiles in infants who were treated with intravitreal injection of bevacizumab (IVB) for type 1 retinopathy of prematurity (ROP) with age-matched preterm non-ROP infants. Thirteen infants with type 1 ROP and 13 age-matched
Matthew B Wallenstein et al.
The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians, 29(20), 3317-3322 (2015-12-25)
To identify associations between second-trimester serum inflammatory biomarkers and preterm birth among obese women. In this nested case-control study, we compared 65 serum inflammatory biomarkers in obese women whose pregnancies resulted in early spontaneous preterm birth (<32 weeks gestation, n = 34)